Abstract:The COVID-19 disease is caused by a new strain of the coronavirus family (SARS-CoV-2), and it has affected at present millions of people all over the world. The indispensable role of the main protease (Mpro) in viral replication and gene expression makes this enzyme an attractive drug target. Therefore, inhibition of SARS-CoV-2 Mpro as a proposition to halt virus ingression is being pursued by scientists globally. Here we carried out a study with two objectives: the first being to perform comparative protein sequence and 3D structural analysis to understand the effect of 12 point mutations on the active site. Among these, two mutations, viz., Ser46 and Phe134, were found to cause a significant change at the active sites of SARS-CoV-2. The Ser46 mutation present at the entrance of the S5 subpocket of SARS-CoV-2 increases the contribution of other two hydrophilic residues, while the Phe134 mutation, present in the catalytic cysteine loop, can cause an increase in catalytic efficiency of Mpro by facilitating fast proton transfer from the Cys145 to His41 residue. It was observed that active site remained conserved among Mpro of both SARS-CoVs, except at the entrance of the S5 subpocket, suggesting sustenance of substrate specificity. The second objective was to screen the inhibitory effects of three different data sets (natural products, coronaviruses main protease inhibitors, and FDA-approved drugs) using a structure-based virtual screening approach. A total of 73 hits had a combo score >2.0. Eight different structural scaffold classes were identified, such as one/two tetrahydropyran ring(s), dipeptide/tripeptide/oligopeptide, large (approximately 20 atoms) cyclic peptide, and miscellaneous. The screened hits showed key interactions with subpockets of the active site. Further, molecular dynamics studies of selected screened compounds confirmed their perfect fitting into the subpockets of the active site. This study suggests promising structures that can fit into the SARS-CoV-2 Mpro active site and also offers direction for further lead optimization and rational drug design.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00546?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00546</a>.Phylogenetic relationship of SARS-CoV-2 Mpro; superimposed cocrystallized and redocked ligand; protein thermodynamic stability information upon point mutations; list of top Mpro inhibitors with their structures, source and scaffold information; interaction fraction histogram obtained from MD simulations; protein-ligand contact timeline information; RMSF plot for protein in presence of different ligands; binding free energy plot; and analysis of impact of mutation on active site residues of Mpro (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00546/suppl_file/ci0c00546_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Targeting the Main Protease (M pro , nsp5) by Growth of Fragment Scaffolds Exploiting Structure-Based Methodologies

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease

High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease

Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors

Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

De novo Design of SARS-CoV-2 Main Protease Inhibitors

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

Novel Small-Molecule Scaffolds as Candidates against the SARS Coronavirus 2 Main Protease: A Fragment-Guided in Silico Approach

Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors

Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

Insights into the Main Protease of SARS-CoV-2: Thermodynamic Analysis, Structural Characterization, and the Impact of Inhibitors

Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: Unveiling new therapeutic avenues against SARS-CoV-2